Abstract:Normalizing the tumor‐induced immune deficiency in the immunosuppressive tumor microenvironment (TME) through increasing the efficient infiltration and activation of antitumoral immunity in TME is the core of promising immunotherapy. Herein, a Cyclo(Arg‐Gly‐Asp‐d‐Phe‐Lys) (RGD) peptides‐modified combinatorial immunotherapy system based on the self‐assembly of the nanoparticles named RGD‐DMA composed of RGD‐PEG‐PLA, methoxy poly(ethylene glycol)‐poly(lactide) (MPEG‐PLA) and 1,2‐Dioleoyl‐3‐trimethylammonium‐propane (DOTAP) is used to codeliver the immunostimulatory chemokine CCL19‐encoding plasmid DNA (CCL19 pDNA) and immune checkpoint ligand PD‐L1 inhibitor (BMS‐1). The RGD‐DMA/pCCL19‐BMS‐1 system not only exhibited significant inhibition of tumor progression but also induced locally high concentrations of immunostimulatory cytokines at tumor sites without causing an obviously systemic inflammatory response. The immunosuppressive TME is efficaciously reshaped by the coadministration of RGD‐DMA/pCCL19 and BMS‐1, as indicated by the activated T lymphocytes, increased intratumoral‐infiltration of mature dendritic cells (DCs), and the repolarization of macrophages from pro‐tumoral M2‐phenotype toward tumoricidal M1‐phenotype. The upregulated PD‐L1 expression at tumor sites caused by the increased IFN‐γ levels after immunostimulatory gene therapy further demonstrated the synergistic effects of BMS‐1 in counteracting the inhibitory role of PD‐L1 expression in antitumor immunity. Therefore, the combination of immunostimulating therapy and immune checkpoint inhibitor that synergistically target multiple immune regulatory pathways demonstrates significant potential as a novel immunotherapy approach. The combined immunotherapy by RGD‐DMA nanoparticles delivering pDNA encoding the immunostimulating chemokine CCL19 with immune checkpoint small molecular inhibitor BMS‐1 synergistically targets multiple immune regulatory pathways, as indicated by inducing the activation of lymphocytes, repolarizing tumor‐associated macrophages toward a tumoricidal M1 phenotype as well as promoting the maturation of tumor‐infiltrating dendritic cells in the tumor microenvironment (TME). The codelivery of CCL19 plasmid DNA and BMS‐1 by RGD‐DMA significantly reshapes the immunosuppressive TME and leads to a strong antitumor effect.

Immune Checkpoint Reprogramming Via Sequential Nucleic Acid Delivery Strategy Optimizes Systemic Immune Responses for Gastrointestinal Cancer Immunotherapy

Tumor Microenvironment-Modulated Multiple Nanotherapeutic System for Potent Cancer Immunotherapy and Metastasis Inhibition

Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors.

Nanoparticle-Mediated in Situ Molecular Reprogramming of Immune Checkpoint Interactions for Cancer Immunotherapy

Simultaneous Knockdown of Immune Suppressive Markers by Tumor Microenvironment-Responsive Multifaceted Prodrug Nanomedicine

Amplified cancer immunotherapy of PD-L1 blockade by sequential tumor microenvironment reshaping and DC maturation

Triple-Combination Immunogenic Nanovesicles Reshape the Tumor Microenvironment to Potentiate Chemo-Immunotherapy in Preclinical Cancer Models

A cascade targeting strategy based on modified bacterial vesicles for enhancing cancer immunotherapy

Immunostimulatory CKb11 gene combined with immune checkpoint PD-1/PD-L1 blockade activates immune response and simultaneously overcomes the immunosuppression of cancer

Rational administration sequencing of immunochemotherapy elicits powerful anti-tumor effect

Tumor microenvironment reprogramming combined with immunogenic enhancement by nanoemulsions potentiates immunotherapy

In vivo activated T cell targeting with PD-1/PD-L1 blockade for sequential treatment mediated cancer immunotherapy

Co-delivery of Phagocytosis Checkpoint Silencer and Stimulator of Interferon Genes Agonist for Synergetic Cancer Immunotherapy

A Checkpoint‐Regulatable Immune Niche Created by Injectable Hydrogel for Tumor Therapy

Synergy of Immunostimulatory Genetherapy with Immune Checkpoint Blockade Motivates Immune Response to Eliminate Cancer

Few-Layer Bismuthene for Checkpoint Knockdown Enhanced Cancer Immunotherapy with Rapid Clearance and Sequentially Triggered One-for-All Strategy

Anti-PD-L1 mediating tumor-targeted codelivery of liposomal irinotecan/JQ1 for chemo-immunotherapy

In Situ Reprogramming of Tumors for Activating the OX40/OX40 Ligand Checkpoint Pathway and Boosting Antitumor Immunity

Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches

Reshaping Antitumor Immunity with Chemo‐Photothermal Integrated Nanoplatform to Augment Checkpoint Blockade‐Based Cancer Therapy

Overcoming immune resistance by sequential prodrug nanovesicles for promoting chemoimmunotherapy of cancer